Список проголосовавших за комментарий " On The Wires<ul><li>Interpace Diagnostics Group (<strong>IDXG</strong>) announced the acceptance of four posters to be presented at the upcoming United States and Canadian Academy of Pathology (USCAP) meeting being held March 4-10, 2017 in San Antonio, Texas. The posters reflect a review of data from the Company's extensive experience in molecular thyroid testing, including experience with over 5000 analyses of indeterminate thyroid nodules using its combined mutational (ThyGenX) and microRNA classifier (ThyraMIR) testing format. Fundamental insights into the mechanism of thyroid cancer development and progression are reported as well as a comprehensive statistical analysis of the mutational and microRNA profiling features representing the largest integrated analysis of DNA and RNA alterations in existence for commercially available molecular products in the area of thyroid cancer.</li><li>Raytheon Company (<strong>RTN</strong>) demonstrated, in a recent flight test, single-ship geolocation capability for the ALR-69A(V), a first for any radar warning receiver.<br/> The AN/ALR-69A(V) — the world's first all-digital radar warning receiver — enhances aircrew survivability, providing «sensors forward» situational awareness at lower costs than competing systems through simple software modifications.</li><li>NAPCO Security Technologies (<strong>NSSC</strong>) announced it has formally launched its Starlink Connect Radio product. The radio was recently showcased at the ISC East security trade show in New York and was well received by the security professionals in attendance.</li><li>Cellular Biomedicine Group (<strong>CBMG</strong>) announced that the governing Board of the California Institute for Regenerative Medicine, California's stem cell agency, has awarded the Company $2.29 million to support pre-clinical studies of AlloJoinTM, CBMG's «Off-the-Shelf» Allogeneic Human Adipose-derived Mesenchymal Stem Cells for the treatment of Knee Osteoarthritis in the United States.</li><li>Cherwell Software announced it has secured $50 million in funding from KKR (<strong>KKR</strong>). KKR is making the investment through its Next Generation Technology Fund, which focuses on investments in software, security, Internet, digital media, and information services.</li><li>Aimmune Therapeutics (<strong>AIMT</strong>) announced that new clinical data on AR101 will be presented during poster sessions on Monday, March 6, at the 2017 American Academy of Allergy, Asthma & Immunology Annual Meeting taking place March 3--6, 2017, in Atlanta, Georgia. The presentations will report data from the Phase 2 ARC001 study (Abstract 803) and from the screening population of the PALISADE Phase 3 study (Abstracts L20 and 807). </li></ul>"